Bayer submits Algeta's radium-223 dichloride in US and EU
This article was originally published in Scrip
Executive Summary
Bayer HealthCare has submitted a new drug application to the US FDA and a marketing authorization application to the European Medicines Agency for radium-223 dichloride (radium-223) for the treatment of castration-resistant prostate cancer patients with bone metastases.